Patton Albertson Miller Group LLC lowered its position in Johnson & Johnson (NYSE:JNJ) by 4.8% during the second quarter, according to its most recent filing with the SEC. The institutional investor owned 24,553 shares of the company’s stock after selling 1,243 shares during the period. Johnson & Johnson accounts for approximately 1.4% of Patton Albertson Miller Group LLC’s portfolio, making the stock its 12th biggest holding. Patton Albertson Miller Group LLC’s holdings in Johnson & Johnson were worth $3,254,000 at the end of the most recent quarter.

A number of other hedge funds have also recently made changes to their positions in JNJ. State Street Corp lifted its holdings in Johnson & Johnson by 4.3% in the 1st quarter. State Street Corp now owns 160,223,321 shares of the company’s stock valued at $19,955,806,000 after purchasing an additional 6,656,371 shares in the last quarter. Harbour Capital Advisors LLC lifted its holdings in Johnson & Johnson by 13,327.8% in the 2nd quarter. Harbour Capital Advisors LLC now owns 2,501,472 shares of the company’s stock valued at $18,909,000 after purchasing an additional 2,482,843 shares in the last quarter. Canada Pension Plan Investment Board lifted its holdings in Johnson & Johnson by 33.9% in the 2nd quarter. Canada Pension Plan Investment Board now owns 4,696,566 shares of the company’s stock valued at $621,309,000 after purchasing an additional 1,189,900 shares in the last quarter. Bank of Nova Scotia lifted its holdings in Johnson & Johnson by 94.5% in the 1st quarter. Bank of Nova Scotia now owns 1,171,517 shares of the company’s stock valued at $145,914,000 after purchasing an additional 569,313 shares in the last quarter. Finally, Oppenheimer Asset Management Inc. purchased a new position in Johnson & Johnson in the 1st quarter valued at $65,598,000. Institutional investors own 65.61% of the company’s stock.

Shares of Johnson & Johnson (NYSE JNJ) opened at $138.01 on Friday. The company has a current ratio of 1.32, a quick ratio of 1.02 and a debt-to-equity ratio of 0.36. The stock has a market capitalization of $370,766.63, a PE ratio of 19.33, a P/E/G ratio of 2.80 and a beta of 0.82. Johnson & Johnson has a 52-week low of $109.32 and a 52-week high of $144.35.

Johnson & Johnson (NYSE:JNJ) last issued its quarterly earnings data on Tuesday, October 17th. The company reported $1.90 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $1.80 by $0.10. The firm had revenue of $19.65 billion during the quarter, compared to the consensus estimate of $19.29 billion. Johnson & Johnson had a return on equity of 27.38% and a net margin of 21.28%. The company’s quarterly revenue was up 10.3% on a year-over-year basis. During the same period last year, the company earned $1.68 EPS. analysts predict that Johnson & Johnson will post 7.28 earnings per share for the current fiscal year.

The firm also recently disclosed a quarterly dividend, which will be paid on Tuesday, December 12th. Investors of record on Tuesday, November 28th will be given a dividend of $0.84 per share. This represents a $3.36 dividend on an annualized basis and a dividend yield of 2.43%. The ex-dividend date of this dividend is Monday, November 27th. Johnson & Johnson’s payout ratio is 58.33%.

A number of brokerages have weighed in on JNJ. Citigroup Inc. raised their price objective on Johnson & Johnson from $140.00 to $149.00 and gave the company a “buy” rating in a report on Monday, October 23rd. Vetr raised Johnson & Johnson from a “sell” rating to a “hold” rating and set a $137.71 target price for the company in a research note on Monday, October 30th. Leerink Swann reaffirmed an “outperform” rating and issued a $165.00 target price (up from $150.00) on shares of Johnson & Johnson in a research note on Wednesday, October 18th. Royal Bank Of Canada raised their target price on Johnson & Johnson from $144.00 to $147.00 and gave the stock an “outperform” rating in a research note on Wednesday, October 18th. Finally, Stifel Nicolaus raised their target price on Johnson & Johnson from $140.00 to $142.00 and gave the stock a “hold” rating in a research note on Wednesday, October 18th. Four equities research analysts have rated the stock with a sell rating, eight have assigned a hold rating and eleven have given a buy rating to the stock. Johnson & Johnson presently has a consensus rating of “Hold” and an average price target of $143.70.

WARNING: “Patton Albertson Miller Group LLC Decreases Holdings in Johnson & Johnson (JNJ)” was first reported by Watch List News and is the property of of Watch List News. If you are accessing this news story on another publication, it was illegally copied and republished in violation of U.S. and international trademark & copyright laws. The original version of this news story can be read at https://www.watchlistnews.com/patton-albertson-miller-group-llc-decreases-holdings-in-johnson-johnson-jnj/1727442.html.

Johnson & Johnson Company Profile

Johnson & Johnson is a holding company, which is engaged in the research and development, manufacture and sale of a range of products in the healthcare field. It operates through three segments: Consumer, Pharmaceutical and Medical Devices. Its primary focus is products related to human health and well-being.

Want to see what other hedge funds are holding JNJ? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Johnson & Johnson (NYSE:JNJ).

Institutional Ownership by Quarter for Johnson & Johnson (NYSE:JNJ)

Receive News & Ratings for Johnson & Johnson Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Johnson & Johnson and related companies with Analyst Ratings Network's FREE daily email newsletter.